



Advances in the Discovery of Novel Antibiotics

Guest Editor:

Dr. Younes Smani

Institute of Biomedicine of
Seville, University of Seville,
41013 Seville, Spain

Deadline for manuscript
submissions:

closed (31 July 2022)

Message from the Guest Editor

The development of non-traditional therapeutic strategies such as repurposed drugs, immunomodulators, bacteriophages, and antivirulence therapeutics for use alone or together with clinically relevant antibiotics has become exigent. The goal of this Special Issue is to systematically provide an overview on the scientific evidence on the therapeutic potential of novel drugs against Gram-negative and Gram-positive bacteria. In specific, we aim to:

- i) Discuss the therapeutic potential of this drug class;
- ii) Identify their potential targets and their mechanisms of action, including DNA, RNA and proteins inhibitors, quorum sensing regulators, biofilm formation inhibitors and disruptors, drugs that interact with the cell membrane and iron metabolism, and host immune system modulators, among others;
- iii) Summarize the outcomes of advanced preclinical trials for treating bacterial infections.

We welcome researchers to submit original research, reviews, or perspectives focusing on novel antibiotic drugs for treatment against bacteria.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)